använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.


Vator Securities advises Precise Biometrics on 23 MSEK Directed Share Issue

30 November 2021

Precise Biometrics is a global identification software provider, offering products with a range of application for identification in a convenient and secure way. Precise offers products with various applications that enable individuals to identify themselves by using biometrics.

Precise intends to use the net proceeds from the directed issue to finance part of the company’s acquisition of EastCoast Solutions.

Read More

Vator Securities advises SenzaGen on 30 MSEK Directed Share Issue

29 October 2021

SenzaGen aims to be a leader in non-animal toxicology testing driving the transition from animal testing to methods better suited to reflect human biology.

The company has a growth strategy which involve continued commercialization of the in house developed GARD® test platform, expansion of the test portfolio with a broader range of tests and pursuing acquisition opportunities of profitable and growing companies with complementary offerings

Read More

Unleashing a paradigm shift in early detection of pancreatic cancer

24 September 2021

Advancing into commercial phase, Immunovia has achieved a strong launch of its first product IMMray PanCan-d which was shortly followed by backing of the largest US patient organization Pancreatic Cancer Action Network (PanCAN) and the US National Pancreas Foundation (NPF).

Such support provides real-world commercial third-party validation and should reinforce the capital market’s confidence in the test’s performance and clinical utility offer.

Read More

Vator Securities advises Sprint Bioscience on 67 MSEK Rights Issue

7 September 2021

Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 67,6 million.

Sprint Bioscience develops small-molecule first-in-class drug projects with a focus on oncology. Using fragment-based drug discovery, the company develops drug projects in a time- and resource-efficient way. These are then out-licensed to global drug companies during the preclinical phase.

Read More

Vator Securities advises Umecrine Cognition on 35 MSEK Private Placement

26 July 2021

Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 35,1 million.

Umecrine Cognition is developing golexanolone, a drug candidate with a completely new type of mechanism of action targeting the GABAA receptor in the brain.

Read More

Vator Securities advises Plastics Unbound on 30 MSEK Private Placement

12 July 2021

Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 30,3 million.

Plastics Unbound has successfully completed technical and commercial validation through Tier-1 customer trials and production applications and is now transitioning into larger volume orders.

Read More

Vator Swiss Nordic Bio 2022

9 July 2021

VATOR SWISS NORDIC BIO 2022 – The Leading Annual European Healthcare Investor Summit in Zürich.

Vator Securities and Business Sweden & partners have the pleasure to invite you to the annual European healthcare investor conference VATOR SWISS NORDIC BIO, connecting fast growing Nordic publicly listed healthcare companies, the most exciting start-ups, and the European investor community

Read More

Vator Securities advises Xintela on 28 MSEK Directed Share Issues

17 June 2021

Vator Securities acts as Sole Bookrunner in connection with the transactions raising SEK approximately SEK 28 million.

Xintela is developing novel stem cell therapies and antibody based targeted cancer therapies using on the integrin marker technology platform XINMARK®. The patented stem cell product XSTEM®, produced in Xintela’s own GMP-facility, is entering a clinical phase I/IIa study in 2021. 

Read More